Research and Markets (http://www.researchandmarkets.com/research/s6h8z7/bax855)
has announced the addition of the "BAX-855
(Hemophilia A and B) - Forecast and Market Analysis to 2022"
report to their offering.
The competitive landscape of hemophilia A and B recombinant therapy in
the US and 5EU is dominated by the use of recombinant FVIII and FIX
replacement factors, and patients with severe forms of the disease
receive frequent prophylactic infusions beginning from the first one or
two years of life and often continuing through adulthood. However, the
burden on patients and their families to maintain the prophylactic
treatment schedule is high, and there is a significant unmet need for
new therapies that can reduce th number of weekly prophylactic
infusions and alleviate some of this treatment burden.
Baxter's hemophilia A pipeline features BAX-855, a pegylated version of
Advate, the company's recombinant FVIII replacement therapy. The
addition of the PEG moiety increases the half-life of circulating
protein, potentially reducing the number of infusions required for
- Overview of Hemophilia A and B, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on BAX-855 including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for BAX-855 for the top nine countries from 2012 to
- Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan, Argentina and China.
Key Topics Covered:
List of Tables
List of Figures
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/s6h8z7/bax855
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To NFVZone's Homepage ]